Human immunodeficiency virus infection

Active Ingredient: Lamivudine

Indication for Lamivudine

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)
Therapeutic intent: Curative procedure

Lamivudine is indicated as part of antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infected adults.

For this indication, competent medicine agencies globally authorize below treatments:

150 mg twice daily or 300 mg once daily

For:

Dosage regimens

Regimen A: Oral, 150 milligrams lamivudine, 2 times daily.

Regimen B: Oral, 300 milligrams lamivudine, once daily.

Detailed description

The recommended dose of lamivudine is 300 mg daily. This may be administered as either 150 mg twice daily or 300 mg once daily.

Dosage considerations

Lamivudine may be administered with or without food.

150-300 mg or 10 mg/kg daily based on body weight and age

For:

Dosage regimens

Regimen A: In case that patient weight is ≥ 25 kg, oral, 150 milligrams lamivudine, 2 times daily.

Regimen B: In case that patient weight is ≥ 25 kg, oral, 300 milligrams lamivudine, once daily.

Regimen C: In case that patient weight is ≥ 20 kg and patient weight is ≤ 25 kg, oral, 225 milligrams lamivudine, divided 2 times daily.

Regimen D: In case that patient weight is ≥ 20 kg and patient weight is ≤ 25 kg, oral, 225 milligrams lamivudine, once daily.

Regimen E: In case that patient weight is ≥ 14 kg and patient weight is ≤ 20 kg, oral, 75 milligrams lamivudine, 2 times daily.

Regimen F: In case that patient weight is ≥ 14 kg and patient weight is ≤ 20 kg, oral, 150 milligrams lamivudine, once daily.

Regimen G: In case that patient age in years is ≥ 1, oral, 5 milligrams lamivudine per kilogram of body weight, 2 times daily.

Regimen H: In case that patient age in years is ≥ 1, oral, 10 milligrams lamivudine per kilogram of body weight, once daily.

Regimen I: In case that patient age in years is ≤ 1, oral, 5 milligrams lamivudine per kilogram of body weight, 2 times daily.

Regimen J: In case that patient age in years is ≤ 1, oral, 10 milligrams lamivudine per kilogram of body weight, once daily.

Detailed description

Children weighing at least 25 kg

The recommended dose of lamivudine is 300 mg daily. This may be administered as either 150 mg twice daily or 300 mg once daily.

Children weighing less than 25 kg

Children weighing ≥20 kg to <25 kg: The recommended dose is 225 mg daily. This may be administered as either 75 mg taken in the morning and 150 mg taken in the evening, or 225 mg taken once daily.

Children weighing 14 to <20 kg: The recommended dose is 150 mg daily. This may be administered as 75 mg taken twice daily, or 150 mg taken once daily.

Children from three months of age: The limited data available are insufficient to propose specific dosage recommendations.

Children less than three months of age: The limited data available are insufficient to propose specific dosage recommendations.

Children from one year of age: The recommended dose is 5 mg/kg twice daily, or 10 mg/kg once daily.

Children from three months to one year of age: The recommended dose is 5 mg/kg twice daily. If a twice daily regimen is not feasible, a once daily regimen 10 mg/kg/day could be considered. It should be taken into account that data for the once daily regimen are very limited in this population.

Patients changing from the twice daily dosing regimen to the once daily dosing regimen should take the recommended once daily dose (as described above) approximately 12 hours after the last twice daily dose, and then continue to take the recommended once daily dose (as described above) approximately every 24 hours. When changing back to a twice daily regimen, patients should take the recommended twice daily dose approximately 24 hours after the last once daily dose.

Dosage considerations

Lamivudine may be administered with or without food.

Active ingredient

Lamivudine

Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.

Read more about Lamivudine

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.